Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock - Currency: USD

9.39  -0.44 (-4.48%)

Fundamental Rating

3

Overall CRVO gets a fundamental rating of 3 out of 10. We evaluated CRVO against 549 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRVO as it has an excellent financial health rating, but there are worries on the profitability. CRVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRVO had negative earnings in the past year.
In the past year CRVO has reported a negative cash flow from operations.
CRVO had negative earnings in each of the past 5 years.
CRVO had a negative operating cash flow in each of the past 5 years.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CRVO has a Return On Assets of -59.38%. This is comparable to the rest of the industry: CRVO outperforms 42.44% of its industry peers.
CRVO has a Return On Equity (-67.62%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -59.38%
ROE -67.62%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

CRVO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRVO has been increased compared to 5 years ago.
CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 7.87 indicates that CRVO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.87, CRVO belongs to the top of the industry, outperforming 83.79% of the companies in the same industry.
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.87
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

CRVO has a Current Ratio of 8.20. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.20, CRVO is in the better half of the industry, outperforming 73.59% of the companies in the same industry.
A Quick Ratio of 8.20 indicates that CRVO has no problem at all paying its short term obligations.
The Quick ratio of CRVO (8.20) is better than 73.95% of its industry peers.
Industry RankSector Rank
Current Ratio 8.2
Quick Ratio 8.2
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CRVO have decreased strongly by -48.30% in the last year.
The Revenue for CRVO has decreased by -19.47% in the past year. This is quite bad
EPS 1Y (TTM)-48.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.26%
Revenue 1Y (TTM)-19.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.56%

3.2 Future

The Earnings Per Share is expected to grow by 10.81% on average over the next years. This is quite good.
Based on estimates for the next years, CRVO will show a very strong growth in Revenue. The Revenue will grow by 23.02% on average per year.
EPS Next Y-1.7%
EPS Next 2Y5.29%
EPS Next 3Y3.56%
EPS Next 5Y10.81%
Revenue Next Year-33.97%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y23.02%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.29%
EPS Next 3Y3.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERVOMED INC

NASDAQ:CRVO (8/19/2025, 2:08:41 PM)

9.39

-0.44 (-4.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners26.29%
Inst Owner Change-4.4%
Ins Owners25.03%
Ins Owner Change0.23%
Market Cap86.86M
Analysts81.67
Price Target18.02 (91.91%)
Short Float %11.49%
Short Ratio1.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.89%
Min EPS beat(2)-8.93%
Max EPS beat(2)16.71%
EPS beat(4)1
Avg EPS beat(4)-11.86%
Min EPS beat(4)-30.72%
Max EPS beat(4)16.71%
EPS beat(8)3
Avg EPS beat(8)-4.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.29%
Min Revenue beat(2)-0.58%
Max Revenue beat(2)9.17%
Revenue beat(4)2
Avg Revenue beat(4)-2.02%
Min Revenue beat(4)-37.98%
Max Revenue beat(4)21.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.58%
PT rev (3m)11.58%
EPS NQ rev (1m)-10.94%
EPS NQ rev (3m)-51.47%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)22.06%
Revenue NQ rev (3m)58.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.17
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 2.6
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.84
BVpS3.62
TBVpS3.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.38%
ROE -67.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.2
Quick Ratio 8.2
Altman-Z 7.87
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.26%
EPS Next Y-1.7%
EPS Next 2Y5.29%
EPS Next 3Y3.56%
EPS Next 5Y10.81%
Revenue 1Y (TTM)-19.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.56%
Revenue Next Year-33.97%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y23.02%
EBIT growth 1Y-146.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.77%
EBIT Next 3Y-60.37%
EBIT Next 5Y-24.41%
FCF growth 1Y-68.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.42%
OCF growth 3YN/A
OCF growth 5YN/A